ISIS-SMNRx: Phase II start

This month, Isis will begin an open-label, dose-escalation, North American Phase II trial to evaluate 3 intrathecal injections of ISIS-SMNRx in 8 infants with SMA ages 3 weeks to 7 months. Dosing of t...